Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1978 Sep;21(3):714–720. doi: 10.1128/iai.21.3.714-720.1978

Phagocytosis of Cryptococcus neoformans by normal and thioglycolate-activated macrophages.

F J Swenson, T R Kozel
PMCID: PMC422057  PMID: 361575

Abstract

Phagocytosis of Cryptococcus neoformans by normal and thioglycolate-activated mouse peritoneal macrophages was studied. Thioglycolate-activated macrophages exhibited a lower percent phagocytosis than did normal macrophages. Differences in phagocytosis could not be attributed to differences in macrophage viability, minor variations in the concentration of adherent macrophages, or a general depression in activated macrophage phagocytosis. Thioglycolate-activated macrophages required heat-labile opsonins for optimal phagocytosis of non-encapsulated cryptococci, whereas nonactivated macrophages did not require heat-labile opsonins for phagocytosis of the yeast. Both types of macrophages exhibited similar sensitivity to the phagocytosis-inhibiting properties of cryptococcal polysaccharide. The results show that depletion of heat-labile opsonins from serum or inactivation of yeast-bound, heat-labile opsonins by polysaccharide cannot account for the phagocytosis-inhibiting properties of cryptococcal polysaccharide.

Full text

PDF
714

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bianco C., Griffin F. M., Jr, Silverstein S. C. Studies of the macrophage complement receptor. Alteration of receptor function upon macrophage activation. J Exp Med. 1975 Jun 1;141(6):1278–1290. doi: 10.1084/jem.141.6.1278. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Diamond R. D., May J. E., Kane M. A., Frank M. M., Bennett J. E. The role of the classical and alternate complement pathways in host defenses against Cryptococcus neoformans infection. J Immunol. 1974 Jun;112(6):2260–2270. [PubMed] [Google Scholar]
  3. Diamond R. D., Root R. K., Bennett J. E. Factors influencing killing of Cryptococcus neoformans by human leukocytes in vitro. J Infect Dis. 1972 Apr;125(4):367–376. doi: 10.1093/infdis/125.4.367. [DOI] [PubMed] [Google Scholar]
  4. Hamburger J. "Macrophage activation" imperfect terminology hiding imperfect knowledge. Ann Immunol (Paris) 1977 Apr-Jun;128C(3):731–732. [PubMed] [Google Scholar]
  5. Hoff R. Killing in vitro of Trypanosoma cruzi by macrophages from mice immunized with T. cruzi or BCG, and absence of cross-immunity on challege in vivo. J Exp Med. 1975 Aug 1;142(2):299–311. doi: 10.1084/jem.142.2.299. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Kozel T. R., Cazin J. Nonencapsulated Variant of Cryptococcus neoformans I. Virulence Studies and Characterization of Soluble Polysaccharide. Infect Immun. 1971 Feb;3(2):287–294. doi: 10.1128/iai.3.2.287-294.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Kozel T. R., Mastroianni R. P. Inhibition of phagocytosis by cryptococcal polysaccharide: dissociation of the attachment and ingestion phases of phagocytosis. Infect Immun. 1976 Jul;14(1):62–67. doi: 10.1128/iai.14.1.62-67.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Kozel T. R. Non-encapsulated variant of Cryptococcus neoformans. II. Surface receptors for cryptococcal polysaccharide and their role in inhibition of phagocytosis by polysaccharide. Infect Immun. 1977 Apr;16(1):99–106. doi: 10.1128/iai.16.1.99-106.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Mitchell T. G., Friedman L. In vitro phagocytosis and intracellular fate of variously encapsulated strains of Cryptococcus neoformans. Infect Immun. 1972 Apr;5(4):491–498. doi: 10.1128/iai.5.4.491-498.1972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Morland B., Kaplan G. Macrophage activation in vivo and in vitro. Exp Cell Res. 1977 Sep;108(2):279–288. doi: 10.1016/s0014-4827(77)80035-9. [DOI] [PubMed] [Google Scholar]
  11. Nathan C. F., Karnovsky M. L., David J. R. Alterations of macrophage functions by mediators from lymphocytes. J Exp Med. 1971 Jun 1;133(6):1356–1376. doi: 10.1084/jem.133.6.1356. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Nathan C. F., Terry W. D. Decreased phagocytosis by peritoneal macrophages from BCG-treated mice: induction of the phagocytic defect in normal macrophages with BCG in vitro. Cell Immunol. 1977 Mar 15;29(2):295–311. doi: 10.1016/0008-8749(77)90324-0. [DOI] [PubMed] [Google Scholar]
  13. Nathan C. F., Terry W. D. Differential stimulation of murine lymphoma growth in vitro by normal and BCG-activated macrophages. J Exp Med. 1975 Oct 1;142(4):887–902. doi: 10.1084/jem.142.4.887. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Neta R., Salvin S. B. Cellular immunity in vitro: migration inhibition and phagocytosis. Infect Immun. 1971 Dec;4(6):697–702. doi: 10.1128/iai.4.6.697-702.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Ratzan K. R., Musher D. M., Keusch G. T., Weinstein L. Correlation of increased metabolic activity, resistance to infection, enhanced phagocytosis, and inhibition of bacterial growth by macrophages from Listeria- and BCG-infected mice. Infect Immun. 1972 Apr;5(4):499–504. doi: 10.1128/iai.5.4.499-504.1972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Stubbs M., Kühner A. V., Glass E. A., David J. R., Karnovsky M. L. Metabolic and functonal studies on activated mouse macrophages. J Exp Med. 1973 Feb 1;137(2):537–542. doi: 10.1084/jem.137.2.537. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Werb Z., Gordon S. Elastase secretion by stimulated macrophages. Characterization and regulation. J Exp Med. 1975 Aug 1;142(2):361–377. doi: 10.1084/jem.142.2.361. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Williams D. M., Remington J. S. Effect of human monocytes and macrophages on Trypanosoma cruzi. Immunology. 1977 Jan;32(1):19–23. [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES